Keymed Biosciences Inc. (HKG:2162)
Hong Kong · Delayed Price · Currency is HKD 55.20
-0.65 (-1.16%)
Dec 12, 2025, 3:59 PM HKT
Keymed Biosciences Revenue
Keymed Biosciences had revenue of 498.75M CNY in the half year ending June 30, 2025, with 52.47% growth. This brings the company's revenue in the last twelve months to 872.19M, up 968.17% year-over-year. In the year 2024, Keymed Biosciences had annual revenue of 428.12M with 20.91% growth.
Revenue (ttm)
872.19M CNY
Revenue Growth
+968.17%
P/S Ratio
17.22
Revenue / Employee
693.32K CNY
Employees
1,258
Market Cap
16.45B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 428.12M | 74.03M | 20.91% |
| Dec 31, 2023 | 354.10M | 254.03M | 253.87% |
| Dec 31, 2022 | 100.06M | -10.21M | -9.26% |
| Dec 31, 2021 | 110.27M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| JD Health International | 71.34B |
| BeOne Medicines AG | 38.69B |
| Alibaba Health Information Technology | 36.09B |
| Sino Biopharmaceutical | 33.49B |
| CSPC Pharmaceutical Group | 28.65B |
| WuXi Biologics | 21.98B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| Innovent Biologics | 12.52B |